Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas

NCT02313272 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Malignant Glioma

Interventions

RADIATION: Hypofractionated Stereotactic Irradiation (HFSRT)
DRUG: Pembrolizumab
DRUG: Bevacizumab

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]